Switch to digital pathology bears fruit
Posted 11th March 2022 by Nicholas Noakes
Fully digitising pathology operations has led to greater efficiency, cost savings, and quicker diagnosis for the Laboratory of Pathology East Netherlands (LabPON). The move, made six years ago, is showing measurable benefits and now, the institution is beginning to explore the potential of deep learning computational pathology algorithms, which might push the efficiency gains even further.
Prof Alexi Baidoshvili
Digital Pathology: The Next Hurdles
Posted 31st January 2022 by Nicholas Noakes
A Market on the Rise
There has clearly been a surge in interest for digital pathology adoption over the last two years
Highlights from the 9th Microbiome R&D and Business Collaboration Forum – Europe
Posted 10th January 2022 by Nicholas Noakes
It was clear that microbiome companies have been advancing their programs as rapidly as ever, despite the changes brought about by the global pandemic. Service providers—including drug manufacturing organizations—have been busy during the past year, as they continue actively helping diagnostics and therapeutics companies find solutions to advance their products.
Conversation with Dr Hamid Tizhoosh, Founder of KIMIA Lab and Leading Expert in the Development of Unsupervised AI for Tissue Pathology
Posted 30th September 2021 by Nicholas Noakes
“What we have to learn from day one when we design these AI applications, is that pathology has to come with us. We cannot just design a network as computer scientists and then go to the pathologists just when we need to validate it. The pathologist has to be with us from the start.“
Dr Hamid Tizhoosh
A Paradigm Change in Skin Health
Posted 7th September 2021 by Nicholas Noakes
There has been a rapid acceleration of skin microbiome research. Today about 5% of all microbiome clinical studies and 16% of all probiotic products online are dermatology related. Meanwhile, skin probiotics are growing eight times faster than any other probiotic supplement. In clinical cosmetic studies, the microbiome is the fourth largest category.
Conversation with one of the founders of modern digital pathology
Posted 31st August 2021 by Nicholas Noakes
“Digital pathology has reached the point where if you don’t have digitized slides, you will not be able to do six out of ten things that other pathologists can do today.”
Dr. Anil Parwani
Drug Development for NASH with Fibrosis: Expedited Programs
Posted 30th July 2021 by Nicholas Noakes
George Makar spoke at the Global NASH Congress. He gave a regulatory perspective on Drug Development for NASH with Fibrosis. The views were his own. In part one, we explore expedited programs.
Gut dysbiosis in clinical Huntington’s Disease
Posted 22nd July 2021 by Nicholas Noakes
Speaking at the recent Microbiome R&D and Business Collaboration Forum, Anthony Hannan explored research using mouse models for brain disorders, particularly in Huntington’s disease (HD), schizophrenia, depression, and anxiety disorders. He also examined the role of gene-environment interactions involving mental activity, physical activity, stressors, and diet.
